Journal of Thyroid Disorders & Therapy
Open Access

Neda Rajamand Ekberg

Publications

• Research Letter
  Effect of Pioglitazone on Thyroid Hormones and IGF-I in Patients with Type 2 Diabetes
  Author(s): Lisa Arnetz, Mikael Lantz, Kerstin Brismar, Neda Rajamand Ekberg, Michael Alvarsson and Mozhgan Dorkhan Lisa Arnetz, Mikael Lantz, Kerstin Brismar, Neda Rajamand Ekberg, Michael Alvarsson and Mozhgan Dorkhan
  
  Background: Thyroid hormones induce insulin resistance. Pioglitazone is a peroxisome proliferator activated receptor gamma (PPARγ) agonist, used as treatment of type 2 diabetes (T2D) to increase insulin sensitivity. PPARs and thyroid hormone receptors (TRs) induce intracellular effects through similar molecular mechanisms, and the former may inhibit activation of the latter. Pioglitazone has been shown to increase eye protrusion, a symptom linked both to disturbed thyroid hormone levels and orbital edema secondary to increased IGF-I. Aims: We investigated whether attenuation of insulin resistance with pioglitazone affects thyroid hormone status and IGF-I. Methods: 48 patients with T2D were treated with pioglitazone for 26 weeks. Thyroid hormones and IGF-I were analyzed before and after treatment. .. View More»
  DOI: 10.4172/2167-7948.1000139

  Abstract PDF

Relevant Topics